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In light of the rising prevalence of Alzheimer’s disease (AD), new
strategies to prevent, halt, and reverse this condition are needed
urgently. Perturbations of brain network activity are observed in
AD patients and in conditions that increase the risk of developing
AD, suggesting that aberrant network activity might contribute to
AD-related cognitive decline. Human amyloid precursor protein
(hAPP) transgenic mice simulate key aspects of AD, including path-
ologically elevated levels of amyloid-β peptides in brain, aberrant
neural network activity, remodeling of hippocampal circuits, syn-
aptic deficits, and behavioral abnormalities. Whether these alter-
ations are linked in a causal chain remains unknown. To explore
whether hAPP/amyloid-β–induced aberrant network activity con-
tributes to synaptic and cognitive deficits, we treated hAPP mice
with different antiepileptic drugs. Among the drugs tested, only
levetiracetam (LEV) effectively reduced abnormal spike activity
detected by electroencephalography. Chronic treatment with LEV
also reversed hippocampal remodeling, behavioral abnormalities,
synaptic dysfunction, and deficits in learning and memory in hAPP
mice. Our findings support the hypothesis that aberrant network
activity contributes causally to synaptic and cognitive deficits in
hAPP mice. LEV might also help ameliorate related abnormalities
in people who have or are at risk for AD.
epilepsy | plasticity | therapy | dementia | hyperexcitability
No effective therapies exist to prevent, halt, or reverse Alz-heimer’s disease (AD). Because the number of AD cases is
predicted to rise to over 100 million worldwide by 2050 (1), the
identification of such therapies is both important and urgent. A
large body of work suggesting that amyloid-β (Aβ) peptides
contribute causally to the pathogenesis of AD has resulted in the
development of anti-Aβ therapies, some of which are being
evaluated in advanced clinical trials (2–5). However, it is un-
certain whether these treatment strategies will be efficacious and
safe. In fact, strategies to block the production or enhance the
clearance of Aβ have been associated with serious side effects that
probably are unrelated to the reduction of Aβ levels per se (4, 6).
Thus, it is desirable to identify alternative or complementary
therapeutic strategies to block Aβ-induced neuronal dysfunction.
In this regard, it is interesting that perturbation of neuronal
network activity may be a major and early contributor to AD
pathogenesis (7). Aberrant neuronal network activity is observed
in AD patients and in conditions that increase the risk of de-
veloping AD (7–11). AD patients have an increased incidence of
epileptic seizures, and the incidence is highest in patients with
early-onset AD who overexpress human amyloid precursor
protein (hAPP) and Aβ as a result of hAPP gene duplication or
trisomy 21 or who carry mutations that alter hAPP processing
and Aβ production (7). Transgenic mice with neuronal expres-
sion of mutant APP have pathologically elevated levels of Aβ
in AD-vulnerable brain regions and show epileptiform activity
on EEG recordings as well as synaptic and cognitive deficits
(12–16). However, it remains uncertain if the aberrant network
activity contributes to APP/Aβ-dependent synaptic and cognitive
deficits and whether antiepileptic drugs can reverse these defi-
cits. The current study addresses these questions.
Among multiple antiepileptic drugs tested, only levetiracetam
(LEV) effectively suppressed abnormal spiking activity in hAPP
mice. Chronic treatment with LEV also reversed their behavioral
abnormalities, cognitive impairments, remodeling of hippocam-
pal circuits, and synaptic deficits, suggesting that these alter-
ations are causally linked to aberrant network activity.
Results
LEV Reduces Abnormal Spike Activity in hAPP Mice. hAPPmice from
line J20 (hAPPJ20 mice) have pathologically elevated levels of
human Aβ in the brain and show neuronal network dysfunction,
including frequent abnormal spiking activity and more intermittent
epileptic seizures (12, 15, 17). We used video-EEG recordings in
freely moving hAPPJ20 mice to assess the effect of different Food
and Drug Administration (FDA)-approved antiepileptic drugs on
abnormal spiking activity. An abnormal spike was defined as a brief
(<70 ms), high-voltage deflection on the EEG that was eightfold
greater than the average baseline amplitude measured during the
5 s preceding the deflection. The number of spikes per hour on
subdural EEG recordings was used as the main outcome measure.
Nontransgenic (NTG) mice had no such abnormal spikes, whereas
hAPPmice had∼12 spikes/h (Fig. 1A andB). Spikes were detected
in the frontal and parietal cortices and in the hippocampus (Fig.
S1A). The antiepileptic drugs ethosuximide, gabapentin, phenyt-
oin, pregabalin, valproic acid, and vigabatrin, known for their an-
tiepileptic efficacy in animalmodels and in humans with other types
of epilepsy (18), did not reduce spike frequency significantly in
hAPPmice (Table 1). Phenytoin actually increased abnormal spike
activity in these mice, consistent with previous findings (17), and
pregabalin had a similar effect. In contrast, LEV, a second-gen-
eration antiepileptic drug (19, 20), had potent antiepileptic effects
in hAPP mice. A single injection of LEV rapidly and transiently
reduced spike occurrence in the cortex and hippocampus in a dose-
dependent manner (Fig. 1 A–D, Fig. S1 A and B, and Table 1).
Saline injection did not modify the frequency of spikes (Fig. S2).
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We next explored whether chronic LEV treatment (75
mg·kg−1·d−1) could reduce abnormal spike activity persistently
in hAPP mice. To infuse LEV chronically, osmotic minipumps
were implanted subcutaneously (s.c.). Plasma levels of LEV were
stable throughout the duration of the infusion (28 d) and were
almost undetectable 12 d after the end of the infusion (Fig. 1E).
Spike frequency was measured from the parietal cortex before
(baseline) and repeatedly during continuous infusion of LEV. This
treatment persistently reduced abnormal spike activity to ∼50%
of baseline levels in hAPP mice (Fig. 1F), indicating that mice
did not develop resistance to the effect of LEV at this dose and
that LEV effectively suppressed epileptiform discharges in hAPP
Table 1. Acute effects of different antiepileptic drugs in hAPPJ20 mice
FDA-approved
antiepileptic drugs
Acute injection
dose (mg/kg)
Fraction of mice with
>50% spike reduction
Change in spikes relative
to baseline (%)*
Statistical
significance† Effect
Ethosuximide 400 1/6 −0.8 (± 18.9) P = 0.96 None
Gabapentin 100 0/4 −10.3 (± 12.1) P = 0.45 None
Levetiracetam 200 7/7 −70.6 (± 4.9) P < 0.0001 Suppression
Phenytoin 100 0/3 +183.2 (± 48.7) P = 0.043 Exacerbation
Pregabalin 200 0/3 +87.7 (± 14.6) P = 0.026 Exacerbation
Valproic acid 300 0/4 +20.3 (± 15.4) P = 0.28 None
Vigabatrin 300 0/4 +0.8 (± 15.6) P = 0.96 None
*Over a period of 6 h postinjection.
†One-sample t test compared to baseline.
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Fig. 1. LEV decreases abnormal spike activity in hAPP mice acutely and chronically. Subdural EEG activity from parietal cortices (PC) was recorded in NTG
(n = 3) and hAPPJ20 (n = 16) mice before and after LEV administration. (A) Representative recordings showing typical EEG patterns in NTG and hAPP mice.
hAPP mice displayed frequent epileptiform spikes (marked by magenta arrowheads). Acute LEV injection (200 mg/kg, i.p.) transiently suppressed these
abnormal events in hAPP mice as illustrated by the suppression of spikes in an hAPP mouse 2 h after LEV injection. Right panel shows details of a high-voltage
biphasic spike shaded in magenta on the left. (B) Time course of the LEV effect in the same hAPP mouse. Each bar represents the total number of epileptiform
spikes per hour. (C) Baseline EEGs were recorded for 24 h, and drugs were injected at the end of this recording period. During the first 6 h after the injection,
LEV reduced the number of epileptiform spikes in hAPP mice (n = 16) by ∼75% on average. Subsequently, the frequency of epileptiform spikes increased
gradually, returning to baseline levels by 12–18 h after the injection. (D) Dose-dependent effect of LEV on spike frequency during the first 6 h after the
injection (n = 5–6 hAPP mice per dose). (E) Plasma concentration of LEV in hAPP mice (n = 4) determined during and after chronic infusion of the drug
(75 mg·kg−1·d−1) by s.c. implanted osmotic minipumps. (F) EEGs were recorded in hAPP mice (n = 10) 24 h before (baseline), during, and after continuous
infusion of LEV (75 mg·kg−1·d−1) for 28 d. Spike frequencies were reduced to ∼50% of baseline levels throughout the LEV infusion and returned to baseline
level by 12 d after the end of the treatment. **P < 0.005, ***P < 0.0005 vs. baseline or as indicated by brackets (one-way ANOVA and Bonferroni test). Values
in C–F are means ± SEM.
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mice. Spike frequency returned to baseline levels 2 wk after
cessation of the treatment (Fig. 1F).
Chronic LEV Treatment Reverses Behavioral Abnormalities in hAPP
Mice. Like other APP transgenic lines, hAPPJ20 mice are hy-
peractive in the open field (21, 22) and spend more time than
NTG mice in the open arms in the elevated plus maze (21, 23,
24). Prescreening of untreated mice in an open field at 2.5–3.0
mo of age confirmed the hyperactivity of hAPP mice (Fig. 2A).
Mice were then divided into groups so that baseline activity
levels did not differ between genotype-matched groups that re-
ceived saline or LEV (Fig. 2B). hAPP mice and NTG controls
were tested during chronic infusion of saline or LEV (n = 21–30
mice per genotype and treatment) in the open field and elevated
plus maze at 4–6 mo of age. LEV treatment reversed the ab-
normal increase in ambulations of hAPP mice in the periphery of
the open field, which accounted for most of their hyperactivity
phenotype in this paradigm (Fig. 2C). In the elevated plus maze,
saline-treated hAPP mice showed increased overall ambulations
(Fig. 2D) and spent more time in the open arms as compared
with NTG mice (Fig. 2 E and F and Fig. S3). LEV treatment
reversed these behavioral abnormalities in hAPP mice and did
not significantly affect the behavior of NTG controls (Fig. 2 E
and F and Fig. S3).
Several lines of evidence suggest that abnormal spike activity
can interfere transiently with brain functions (25, 26). To explore
whether behavioral abnormalities in hAPPmice are dependent on
the continual presence of epileptiform discharges, we suppressed
epileptic spike frequency in these mice with a single injection of
LEV and tested their behavior 2 h later. Transient reduction of
abnormal spikes did not acutely reverse their abnormal behaviors
in the open field or elevated plus maze (Fig. S4).
Chronic LEV Treatment Improves Learning and Memory in hAPP Mice.
To determine if chronic LEV treatment ameliorates cognitive
deficits in hAPP mice, we tested hippocampus-dependent learning
and memory in NTG and hAPP mice chronically treated with sa-
line or LEV in two paradigms: habituation to a novel environment
and theMorris water maze. After 12 d of chronic infusion, context-
dependent habituation (learning) and dishabituation (forgetting)
were assessed in a novel environment (open field). Independent of
treatment, NTG and hAPP mice habituated to the open field,
reaching the same level of activity after four trials (Fig. 3A).
However, when mice were retested in the same environment after
an interval of 7 d, saline-treated hAPP mice, but none of the other
groups, showed complete dishabituation to the open field (Fig.
3A) and impairment of memory retention (Fig. 3B). Like saline-
and LEV-treated NTGmice, LEV-treated hAPP mice showed no
dishabituation (Fig. 3A) and no impairment in long-term memory
retention (Fig. 3B), suggesting that LEV improved context-de-
pendent memory or reduced forgetting in hAPP mice.
Spatial learning and memory were then assessed in the Morris
water maze in the same groups of mice after 20 d of chronic
infusion. In the spatial (hidden-platform) component, LEV-
treated hAPP mice learned better and faster than saline-treated
hAPP mice but not as well as NTG controls (Fig. 3C and Fig.
S5A). All groups of mice learned similarly well in the visibly
cued-platform component (Fig. 3C). In a probe trial performed
24 h after completion of the last training trial, only saline-treated
hAPP mice were impaired, showing no preference for the target
quadrant (Fig. 3D). Swim speeds were similar among all groups
of mice during learning and probe trials (Fig. S5 B and C).
To determine whether LEV treatment also improves nonspatial
learning and memory, we tested the effect of LEV in an in-
dependent cohort of mice in a novel object recognition paradigm.
During the training trial, none of the groups showed a preference
for one of the objects (Fig. S6). During the test session, all groups of
mice except the saline-treated hAPP mice interacted longer and
more often with the novel object than with the familiar object (Fig.
3 E and F), demonstrating that LEV also improved nonspatial
learning and memory in hAPP mice.
Chronic LEV Treatment Reverses Synaptic Deficits in the Hippocampus.
Consistent with their hippocampus-dependent memory deficits,
hAPP mice show prominent alterations of synaptic functions in
the dentate gyrus and hippocampal CA1 region (12, 15, 24, 27).
To determine whether chronic LEV treatment improves synaptic
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Fig. 2. LEV treatment reverses behavioral abnormalities in hAPP mice. Be-
havioral testing was performed in two independent cohorts of 4- to 6-mo-
old mice. Because results were similar in both cohorts, the data were pooled.
(A and B) Before acute and chronic treatments, mice were prescreened in an
open field for 5 min. (A) hAPPJ20 mice were more active than NTG controls
(***P < 0.0001 by t test). (B) Within each genotype, mice were divided into
two groups, so that baseline activity levels did not differ between groups
before treatment with LEV or saline. Two-way ANOVA revealed a significant
effect of the genotype (P < 0.0001) but not of group (P = 0.61) and no in-
teraction effect (P = 0.43). ***P < 0.0005 vs. NTG (Bonferroni test). (C–F)
hAPP mice and NTG controls were treated chronically with saline or LEV (75
mg·kg−1·d−1, s.c.; n = 21–30 mice per genotype and treatment). (C) Mice
were tested in the open field 8 d (cohort 1) or 19 d (cohort 2) after the
treatment started. The numbers of peripheral and central ambulatory
movements and of fine movements were measured. Amb., ambulation;
Mov., movements. (D–F) Mice were tested in the elevated plus maze 19 d
(cohort 1) or 5 d (cohort 2) after the start of treatment. The total distance
moved (D), the distance moved in the open arms (E), and the percentage of
total time spent in the open arms (F) were measured. Two-way ANOVA
revealed a significant interaction between genotype and treatment [C, P =
0.001 (peripheral ambulation); D, P = 0.007; E, P = 0.003; F, P = 0.012] and
a significant genotype effect [C, P = 0.001 (central ambulation)]. *P < 0.05,
**P < 0.005, ***P < 0.0005 vs. saline-treated NTG or as indicated by bracket
(Bonferroni test). Values are means ± SEM.
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plasticity in the dentate gyrus of hAPP mice, we measured long-
term potentiation (LTP) in acute hippocampal slices from 4- to 5-
mo-old mice after 20–25 d of LEV treatment. Consistent with
previous findings (12, 15, 24, 27), LTP at the perforant path to
dentate granule cell synapse was impaired in hAPP mice (Fig. 4 A
and B). Remarkably, chronic LEV treatment fully reversed LTP
deficits in hAPP mice (Fig. 4 A and B). In parallel, we investigated
whether LEV also improved synaptic transmission strength, which
is impaired in area CA1 of hAPPJ20 mice (12, 15, 24, 27).
Comparisons of input/output curves confirmed the deficit in syn-
aptic transmission strength in saline-treated hAPP mice (Fig. 4C).
Chronic LEV treatment also reversed this deficit (Fig. 4C).
Chronic LEV Treatment Reverses Abnormalities in Synaptic Activity-
Related Proteins. hAPP mice show changes in diverse synaptic
activity-related proteins and prominent remodeling of neuronal
circuits in the dentate gyrus (12, 28). Many of these alterations
are likely compensatory and may help the dentate gyrus (the
“hippocampal gate”) prevent cortical spiking activity from
spreading into the other subfields of the hippocampal formation.
However, as previously suggested, some of the compensatory
changes may themselves interfere with normal synaptic functions
(12, 28, 29). To determine if chronic reduction of abnormal spike
activity reverses alterations in the expression of synaptic activity-
related proteins in hAPP mice, we measured expression levels of
calbindin, neuropeptide Y (NPY), and Fos in the dentate gyrus
of mice treated with saline or LEV for 28 d.
Consistent with previous findings (12, 24, 28), saline-treated
hAPP mice had lower levels of calbindin in the molecular layer
of the dentate gyrus (Fig. 5 A and D), higher levels of NPY in
mossy fibers (Fig. 5 B and E), and fewer Fos-positive cells in the
granular layer (Fig. 5 C and F) than saline-treated NTG controls.
LEV treatment normalized levels of calbindin (Fig. 5 A and D
and Fig. S7) and NPY (Fig. 5 B and E) and increased the number
of Fos-positive cells in the granular layer (Fig. 5 C and F) in
hAPP mice, supporting the notion that these alterations are
triggered and maintained by epileptiform activity.
LEV Does Not Reduce Levels of hAPP, hAPP C-Terminal Fragments, Aβ,
or Aβ Deposition in hAPP Mice. Because Aβ production can be in-
fluenced by neuronal activity (30–33), we examined whether LEV
treatment reduced Aβ levels in brain homogenates and in the in-
terstitial fluid. Aβ levels in the hippocampus of hAPP mice treated
with saline or LEV for 20 d were measured by ELISA at 3 mo of
age (before formation of amyloid plaques). LEV treatment did not
alter Aβ1-x and Aβ1-42 levels or Aβ1-42/Aβ1-x ratios (Fig. 6 A and
B). Chronic LEV treatment also did not change interstitial levels
of Aβx-40 and Aβx-42 or Aβx-42/Aβx-40 ratios, as measured by
microdialysis in the hippocampus of freely moving 3-mo-old hAPP
mice (Fig. 6 C–F). LEV treatment also did not affect levels of full-
length hAPP and hAPP C-terminal fragments in parietal cortex
homogenates (Fig. S8) or early amyloid deposition in the hippo-
campus and cortex (Fig. S9) of 5- to 6-mo-old hAPP mice.
Behavioral and Molecular Abnormalities Recur Within 35 d After the
End of LEV Treatment. To explore whether the beneficial effects of
LEV extend beyond the treatment period, we retested mice 35 d
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Fig. 3. LEV treatment reverses learning and memory deficits in hAPP mice.
hAPPJ20 mice and NTG controls were chronically treated with saline or LEV.
(A) Context-dependent learning and memory in an open field arena. In the
initial phase of this test, all mice (n = 10–15 mice per genotype and treat-
ment) showed habituation to the novel environment, reaching similar levels
of activity on the fourth trial (no treatment or genotype effects and no in-
teraction by two-way repeated-measures ANOVA). However, when rein-
troduced into the same arena 7 d later, saline-treated, but not LEV-treated,
hAPP mice showed clear evidence of abnormal dishabituation (forgetting)
compared with the control groups (P = 0.045 for interaction between ge-
notype and treatment on trial 5 by two-way ANOVA). P < 0.005 vs. LEV-
treated hAPP mice, P < 0.0005 vs. saline-treated NTG mice (Bonferroni test).
Saline-treated hAPP mice were the only group that showed dishabituation in
the open field 7 d after the fourth trial (P = 0.006 by paired t test, comparing
total movements in trial 4 vs. trial 5). (B) Spatial learning and memory index
(ratio of total movements during trials 4 and 5). Two-way ANOVA revealed
a significant interaction between genotype and treatment (P = 0.0031).
***P < 0.0005 vs. saline-treated NTG (Bonferroni test). (C) Learning curves
during spatial training in the Morris water maze (n = 10–15 mice per ge-
notype and treatment). The distance each mouse swam to reach the hidden
platform was recorded during 5 d. Data points represent the average per-
formance of mice during four training trials/d. Repeated-measures ANCOVA
revealed a significant interaction between genotype and day in saline-
treated NTG and hAPP mice (P = 0.0063) and a significant interaction be-
tween LEV treatment and day in hAPP mice (P = 0.022) but not in NTG
controls. (D) Twenty-four hours after the last training session, mice were
tested in a probe trial (platform removed), and the percentage of time mice
spent swimming in the target quadrant was calculated. One-tailed, one-
sample t tests were performed to determine if the mean of each group was
different from chance (dotted line). *P < 0.05, **P < 0.005, ***P < 0.0005 vs.
25%. Only saline-treated hAPP mice did not show a preference for the
target quadrant. Two-way repeated-measures ANOVA revealed a signifi-
cant interaction between genotype and treatment (P = 0.01). Bonferroni
test revealed a significant difference between hAPP/saline and hAPP/LEV
(P = 0.05). (E and F) Novel object recognition performed in an independent
cohort of mice (n = 9–13 mice per genotype and treatment). (E) Preference
index represents the time spent with the novel object (N) divided by the
total time spent with both novel (N) and familiar (F) objects. One-tailed, one-
sample t tests were performed to determine if the mean of each group
was different from chance (dotted line). **P < 0.005, vs. 0.5. (F) Number of
times mice interacted with the novel (N) versus the familiar (F) object during
a 10-min test session. *P < 0.05, **P < 0.005 vs. familiar object (unpaired t
test). Values are means ± SEM.
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after the s.c. minipump infusions were designed to stop. We first
confirmed that LEV was barely detectable in the plasma of hAPP
mice at that time (0.17± 0.08 μg/mLof plasma). hAPPmice that had
been treated with LEV for 28 d showed typical abnormal behaviors
in the open field and elevated plus maze 35 d after the putative end
of the treatment (Fig. 7 A and B). These mice had decreased levels
of calbindin in the molecular layer and of Fos-positive cells in the
granular layer of the dentate gyrus (Fig. 7 C and D).
Loss of Antiepileptic Efficacy of LEV at High Doses Is Associated with
a Loss of Other Beneficial Effects in hAPP Mice. LEV is known to
lose antiepileptic efficacy during sustained treatment at high
doses in rodents (34–36), presumably because of the de-
velopment of functional rather than metabolic tolerance (37). A
small proportion of patients with epilepsy also develop tolerance
to the antiepileptic effects of LEV (37, 38). The mechanisms by
which high-dose LEV induces functional tolerance remain un-
known (37). We confirmed this tolerance effect in hAPP mice
treated with high doses of LEV (150 mg·kg−1·d−1 s.c. plus 1.8 mg/
mL in drinking water) (Fig. 8A). This loss of antiepileptic efficacy
was not caused by a reduction in drug levels, because plasma
levels of LEV in hAPP mice treated with the high dose were
∼fivefold greater than those in hAPP mice treated with the more
efficacious low dose (Fig. 8B). To determine whether chronic
suppression of abnormal spike activity was required for LEV to
exert beneficial effects in hAPP mice, we compared the behav-
ioral performance and molecular alterations in the hippocampus
of NTG and hAPP mice chronically treated with saline or LEV
at low versus high doses. In contrast to low-dose treatment, high-
dose treatment did not reverse behavioral abnormalities (Fig. 8
C and D) or alterations in the expression of synaptic activity-
related proteins (Fig. 8 E and F). These results are consistent
with the finding that LEV improves memory in aged rats with
cognitive impairment at low doses but not at high doses (39) and0 20 40 60
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Fig. 4. LEV reverses deficits in synaptic transmission and plasticity in hAPP
mice. Field recordings were made from acute hippocampal slices obtained
from 4- to 5-mo-old NTG and hAPPJ20 mice treated s.c. with LEV (75
mg·kg−1·d−1) or saline for 20–25 d. (A and B) LTP induction in the dentate
gyrus after theta-burst stimulation of the medial perforant pathway. (A) LTP
curves illustrate the deficit of synaptic plasticity in saline-treated hAPP mice
and the complete reversal of this deficit by LEV treatment. (B) Mean of the
last 10 min of the LTP recordings. LEV treatment normalized LTP deficits in
hAPP mice. Two-way ANOVA revealed a significant interaction between ge-
notype and treatment (P = 0.045). *P < 0.05 vs. saline-treated NTG or as in-
dicated by bracket (Bonferroni test). Number of slices per number of mice for
LTP recordings: NTG/saline, 5/4; NTG/LEV, 4/3; hAPP/saline, 5/5; hAPP/LEV, 7/6.
(C) LEV reversed synaptic transmission deficits in the CA1 region of hAPP mice.
Linear regression analysis of input/output curves revealed that the slope of
saline-treated hAPP mice (2.2 ± 0.3) was significantly lower (P < 0.0001 by
F-test) than the slopes of the other groups (NTG/saline, 4.5 ± 0.4; NTG/LEV,
4.2 ± 0.3; hAPP/LEV, 4.4 ± 0.3). Number of slices per number of mice for input/
output recordings: NTG/saline, 8/6; NTG/LEV, 5/3; hAPP/saline, 13/7; hAPP/LEV,
10/7. Values are mean ± SEM.
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Fig. 5. LEV reverses abnormalities in synaptic activity-related proteins in the
dentate gyrus of hAPP mice. Coronal brain sections from NTG and hAPPJ20
mice treated s.c. with saline or LEV (75 mg·kg−1·d−1) for 28 d (n = 12–16 mice
per genotype and treatment) were immunostained for calbindin, NPY, or
Fos. (A–C) Photomicrographs illustrating calbindin (A), NPY (B), and Fos (C)
alterations in saline-treated hAPP mice and normalization of these bio-
markers in LEV-treated hAPP mice. The relative densitometric measures
obtained for the sections shown in this figure were 1.06 (NTG/saline), 0.97
(NTG/LEV), 0.71 (hAPP/saline), 1.04 (hAPP/LEV) for calbindin (A) and 1.05
(NTG/saline), 0.97 (NTG/LEV), 1.23 (hAPP/saline), 1.01 (hAPP/LEV) for NPY
(B). (D and E) Densitometric quantitation of calbindin in the molecular layer
of the dentate gyrus (D) and of NPY in the mossy fiber pathway (E). (F)
Quantification of Fos-immunoreactive cells in the granular layer of the
dentate gyrus. Two-way ANOVA revealed a significant interaction between
genotype and treatment: (D) P = 0.0001; (E) P = 0.029; (F) P = 0.005. *P <
0.05, **P < 0.005, ***P < 0.0005 vs. saline-treated NTG or as indicated by
bracket (Bonferroni test). Values in D–F are mean ± SEM.
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support the hypothesis that the beneficial effects of LEV in
hAPP mice depend critically on its antiepileptic activity.
Discussion
Pathologically elevated levels of hAPP/Aβ cause an intriguing
combination of cognitive and behavioral alterations, synaptic
deficits, and aberrant network activity (3). The results of the
current study suggest that aberrant network activity is upstream
of and contributes causally to synaptic, cognitive, and behavioral
dysfunctions in hAPP mice. Prolonged reduction of abnormal
spike activity by chronic LEV treatment ameliorated impair-
ments in learning and memory and fully reversed deficits in
synaptic transmission and plasticity in the hippocampus of hAPP
mice. In contrast, brief suppression of abnormal spike activity by
acute LEV injection failed to improve behavioral abnormalities.
These findings raise the intriguing possibility that aberrant net-
work activity contributes to behavioral abnormalities through
subacute or chronic mechanisms, such as the remodeling of
neuronal circuits and changes in the expression of neuronal gene
products. In line with this idea, chronic LEV treatment reversed
abnormalities in the expression of neuronal activity-related
proteins that reflect hippocampal remodeling and correlate well
with cognitive deficits in hAPPJ20 mice (12, 28). In addition, the
recurrence of epileptiform activity after the end of the LEV treat-
ment was accompanied by the reappearance of behavioral and
molecular abnormalities. Furthermore, at high doses LEV lost both
its antiepileptic effect and its beneficial effect on behavioral and
molecular abnormalities in hAPP mice.
The most parsimonious interpretation of these findings is that
LEV exerts its beneficial effects through the following causal
chain: suppression of aberrant network activity, reversal of hip-
pocampal remodeling, and recovery of synaptic and cognitive
functions. An alternative interpretation of our results is that
synaptic, network, cognitive, and behavioral dysfunctions result
from parallel processes triggered by a similar upstream mecha-
nism that is blocked by LEV, for example, glutamate spillover
leading to overactivation of extrasynaptic NMDA receptors, a
process that has been implicated in ictogenesis (40, 41) and Aβ-
induced synaptic dysfunction (42). Additional studies are needed
to address these nonexclusive possibilities and the potential rele-
vance of our findings to the human condition.
Although LEV reduced abnormal spike activity in hAPPJ20
mice both acutely and chronically, calcium-channel modulators
such as gabapentin and ethosuximide, the GABA analog vig-
abatrin, and valproic acid, a drug with multiple putative mech-
anisms of actions, did not show clear antiepileptic efficacy in
hAPPJ20 mice, at least at the doses tested here, suggesting that
the mechanisms targeted by these drugs may not be critically in-
volved in network dysfunction in this model. Why pregabalin
exacerbated epileptiform activity in hAPPJ20 mice is unclear.
The sodium-channel blocker phenytoin showed proepileptic ef-
fects in APdE9 mice carrying hAPP-Swedish and presenilin-1
mutations (43) and clearly worsened epileptic activity in hAPPJ20
mice (Table 1 and ref. 17). The paradoxical effects of potent
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Fig. 6. Prolonged LEV treatment does not alter Aβ levels in the hippo-
campus of hAPP mice. (A and B) Aβ1-x and Aβ1-42 levels and Aβ1–42/Aβ1-x
ratios in the hippocampus of 3-mo-old hAPP mice treated s.c. for 20 d with
saline or LEV (75 mg·kg−1·d−1; n = 8–9 mice per treatment) were determined
by ELISA. LEV treatment did not alter tissue levels of Aβ1-x (P = 0.8) or Aβ1-42
(P = 0.3) or the Aβ1–42/Aβ1-x ratio (P = 0.3). (C–F) Levels of Aβ in the in-
terstitial fluid of the hippocampus were measured by in vivo microdialysis in
5-mo-old hAPP mice treated s.c. for 14 d with saline or LEV (75 mg·kg−1·d−1;
n = 9 mice per treatment). (C and D) Interpolated zero flow method to
quantify the pool of measurable Aβx-40 and Aβx-42 in the hippocampus. (E
and F) LEV treatment did not alter exchangeable levels of Aβx-40 (P = 0.3) or
Aβx-42 (P = 0.5) or the Aβx-42/ Aβx-42 ratio (P = 0.5) by unpaired two-tailed t
test. Values are mean ± SEM.
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Fig. 7. Behavioral abnormalities and hippocampal remodeling in hAPP mice
35 d after the end of LEV treatment. Four- to six-month-old NTG and
hAPPJ20 mice were treated s.c. with saline or LEV (75 mg·kg−1·d−1) for 28 d
(n = 7–9 mice per genotype and treatment). (A and B) Thirty-five days after
the end of the treatment, mice were retested in the open field (A) and the
elevated plus maze (B). Two-way ANOVA revealed a significant effect of
genotype (A, P = 0.0009; B, P = 0.0054) but not treatment (A, P = 0.88; B, P =
0.58) and no interaction between genotype and treatment (A, P = 0.48; B,
P = 0.56). (C and D) Coronal brain sections from these mice were immu-
nostained for calbindin and Fos. Calbindin levels in the molecular layer of
the dentate gyrus were quantified by densitometry (C), and the average
number of Fos-immunoreactive cells in the granular layer of the dentate
gyrus per section was counted (D). Two-way ANOVA revealed a significant
effect of genotype (C and D, P < 0.0001) but not treatment (C, P = 0.22; D, P =
0.73) and no interaction between genotype and treatment (C, P = 0.7; D, P =
0.45). *P < 0.05, **P < 0.005, ***P < 0.0005 vs. saline-treated NTG (Bonfer-
roni test). Values are means ± SEM.
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sodium-channel blockers in hAPPJ20 mice can be explained, at
least in part, by a selective depletion of voltage-gated sodium-
channel subunits in inhibitory interneurons of hAPPJ20 mice;
such depletion is also observed in humans with AD (17). In line
with this interpretation, sodium-channel blockers impair cognition
in patients with dementia (44, 45). In contrast, LEV suppressed
seizures but did not impair cognitive functions in patients with
probable AD and clinically apparent epilepsy (46). Together with
our current findings, these observations suggest that LEV may be
a better choice than sodium-channel blockers for the treatment or
prevention of AD-related neuronal network dysfunction.
The observation that LEV was the only drug tested that was
capable of reducing abnormal spike activity in hAPPJ20 mice
suggests that suppression of hAPP/Aβ-induced neuronal network
dysfunction may depend on a specific activity of LEV. However,
the exact mechanism by which LEV counteracts epileptic activity
is still uncertain. The antiepileptic efficacy of LEV appears to
depend on its binding to the synaptic vesicle protein 2A (SV2A)
(47). Although data obtained in neuronal cultures from SV2A-
knockout mice suggest that SV2A has a role in the vesicular
release machinery (48, 49), it is unclear if and how LEV modifies
SV2A function(s). Interestingly, LEV reduces neurotransmitter
release in a synaptic activity-dependent manner (50, 51) and
particularly in excitatory neurons with a sustained and high fre-
quency of firing (51). In addition, LEV may promote glutamate
uptake by increasing glutamate transporter expression (52). By
modulating presynaptic release or glutamate uptake, LEV might
prevent excessive glutamate accumulation at the synaptic cleft,
preventing overstimulation of postsynaptic glutamate receptors.
This mechanism could counteract the pathogenic effects of Aβ,
which may cause glutamate spillover at the synaptic cleft as a
result of impaired glutamate reuptake (42, 53) and increased
glutamate release (54, 55). LEV has additional effects that po-
tentially could counteract pathogenic hAPP/Aβ effects. For ex-
ample, it reduces calcium release from intracellular stores (56,
57), and this process might help prevent Aβ-induced calcium
dysregulation (58, 59).
Convulsive seizures, which occur more frequently in AD
patients than in control populations, may represent the tip of an
iceberg (3, 7). The incidence of nonconvulsive epileptiform ac-
tivity and related dysrhythmias in patients with mild cognitive
impairment (MCI) and AD is unknown. However, there is plenty
of radiological evidence for aberrant network activity in these
conditions, including excessive activation of specific nodes. For
example, in humans with MCI, functional MRI (fMRI) studies
revealed increased activation in AD-vulnerable brain regions
during memory tasks (8–11, 60). Although it is unknown if the
neural hyperactivation observed in MCI and AD patients is re-
lated to abnormal spike activity, it is noteworthy that epilepti-
form activity in epileptic patients without AD coincides spatially
and temporally with focal hyperactivation on fMRI (61–63). In
addition, a recent study found that LEV treatment of patients
with amnestic MCI, a condition increasingly considered to be an
early stage of AD, suppressed aberrant network activity and im-
proved cognitive performance in a hippocampus-dependent task
(64). These results are consistent with our findings and suggest
that excessive network activity also contributes to cognitive dys-
function in people who are in the process of developing AD.
In conclusion, our study demonstrates that LEV can amelio-
rate hAPP/Aβ-induced network, synaptic, cognitive, and behav-
ioral dysfunctions. Together, our findings and those of Bakker
et al. (64) indicate that targeting aberrant network activity with
LEV or related drugs might be of therapeutic benefit in the
prevention or treatment of AD. To maximize its therapeutic
impact, LEV treatment regimens likely will have to be optimized
further with respect to dosage and onset or length of treatment
and also may have to be combined with other drugs that com-
plement its mode of action. Because LEV is FDA approved and
has a relatively benign side-effect profile, its therapeutic potential
deserves to be further explored in additional studies.
Materials and Methods
Transgenic Mice. hAPPJ20 mice (65, 66) were maintained on a C57BL/6J
background by crossing heterozygous transgenic mice with NTG C57BL/6J
breeders (Jackson Laboratory). Mice had access to food (Picolab Rodent
Diet 20; Labdiet) and water ad libitum. Unless indicated otherwise, all the
experiments were performed on a sex-balanced group at 4–6 mo of age. The
Institutional Animal Care and Use Committee of the University of California,
San Francisco, approved all experiments.
Drug Treatments. Levetiracetam (Sequoia Research Products) was dissolved in
sterile saline solution (0.9% sodium chloride). For the acute experiments, mice
were injected i.p. with saline or various doses of LEV (5, 50, or 200 mg/kg). For
the chronic experiments, mice were implanted s.c. in the interscapular region
with osmotic minipumps (model 2004; Alzet, Durect). Minipumps were filled
with saline or LEV solutions per the manufacturer’s instructions. Model 2004
minipumps delivered fluid at a rate of 0.25 μL/h for 28 d. Concentration
of LEV in each minipump was calculated to infuse 75 mg·kg−1·d−1 or 150
mg·kg−1·d−1. After 24 h of priming in saline solution at 37 °C, minipumps
were surgically implanted in mice anesthetized with 3% isoflurane. Mice
receiving high-dose LEV were implanted with the minipump infusing 150
mg·kg−1·d−1 of LEV and also received LEV in their drinking water (1.8 mg/mL
dissolved in tap water). Ethosuximide (Sigma), pregabalin (Sigma), gaba-
pentin (Sigma), vigabatrin (Tocris), and valproic acid (Sigma) were dissolved
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Fig. 8. Loss of antiepileptic efficacy at high doses is associated with a loss of
beneficial LEV effects on behavioral and molecular abnormalities in hAPP
mice. hAPPJ20 mice were chronically treated with saline or LEV. Two doses
of LEV were compared: 75 mg·kg−1·d−1 delivered s.c. via implanted osmotic
minipumps (low) versus 150 mg·kg−1·d−1 delivered s.c. via implanted osmotic
minipumps plus LEV added to the drinking water at 1.8 mg/mL (high). (A)
EEG activity from parietal cortices was recorded in hAPP mice (n = 4) before
and during high-dose LEV administration. Loss of efficacy in reducing ab-
normal spike activity was first observed at 14 d of treatment. *P < 0.05,
**P < 0.005 vs. baseline (one-way ANOVA and Bonferroni test). (B) Plasma
concentration of LEV in hAPP mice (n = 4) determined after 21 d of chronic
infusion of the drug at low versus high doses. **P < 0.005 (unpaired t test).
(C–F) In an independent cohort of mice, NTG and hAPPJ20 mice were treated
with saline or LEV at low or high doses (n = 10–15 mice per genotype and
treatment). The gray dotted lines in graphs represent the mean of meas-
urements obtained in NTG controls. (C and D) Low-dose but not high-dose
LEV reversed the hyperactivity of hAPPJ20 mice in the open field (C) and
their disinhibition-like behavior in the elevated plus maze (D). (E and F) Low-
dose but not high-dose LEV reversed calbindin depletion in the molecular
layer of the dentate gyrus (E) and ectopic expression of NPY in the mossy
fibers (F) of hAPP mice. *P < 0.05, ***P < 0.0005 vs. hAPP treated with saline
(one-way ANOVA followed by Bonferroni test). Values are means ± SEM.
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in sterile 0.9% sodium chloride; phenytoin was dissolved in sterile PBS. All
acute injections were made i.p.
Plasma LEV Levels. A volume of ∼50 μL of blood was taken from the facial
vein of anesthetized (isoflurane 3%) mice. After centrifugation of blood
samples (500 × g for 7 min, 25 °C), plasma was collected and stored at −80 °C.
Plasma concentrations of LEV were determined by HPLC with tandem mass
spectrometry detection and internal standards (Brainsonline).
EEG Recordings. Mice were implanted for video-EEG monitoring after anes-
thesia with Avertin (tribromoethanol, 250 mg/kg, i.p.). Teflon-coated silver
wire electrodes (0.125-mm diameter) soldered to a multichannel electrical
connector were implanted into the subdural space over the left frontal cortex
[coordinates relative to the bregma were mediolateral (ML), ±1 mm; ante-
roposterior (AP), ±1 mm] and the left and right parietal cortex (ML, ±2 mm,
AP, ±2 mm). The left frontal cortex electrode was used as a reference. For
depth EEG recordings, electrodes were implanted bilaterally into the hippo-
campus [stereotaxic coordinates: from the bregma, ML, ± 1.66 mm; AP, ± 2.46
mm; from the skull surface, dorsoventral (DV), −1.87 mm]. All EEG recordings
were carried out at least 1 wk after surgery on freely moving mice in a re-
cording chamber. Digital EEG activity with video was recorded with the Har-
monie software, version 5.0b (Stellate Systems; Natus). Epileptic spikes were
detected automatically and scored by the Gotman spike and seizure detectors
from Harmonie. EEG traces and videos were inspected systematically for de-
tection of false spikes by an investigator blinded to the treatment and the
genotype of the mice. Spike frequency was measured at baseline during 24-h
EEG recording in each hAPPJ20 mouse, allowing us to assess the effects of
antiepileptic drugs on spike frequency over time within the same mouse.
Behavioral Studies. Open field. Spontaneous activity in open field was mea-
sured in an automated Flex-Field/Open Field Photobeam Activity System (San
Diego Instruments). Before testing, micewere transferred to the testing room
and acclimated for 1 h. Mice were tested in a clear plastic chamber (41 × 41 ×
30 cm) for 5 min, with two 16 × 16 photobeam arrays detecting horizontal
and vertical movements. The apparatus was cleaned with 70% ethanol (by
volume) between testing of each mouse. Total movements (ambulatory
movements in the center and the periphery and fine movements including
rearing) in the open field were recorded for further data analysis. For habit-
uation in the open field (Fig. 3A), mice were retested systematically within the
same chamber.
Elevated plus maze. The elevated plus maze consisted of two open and two
enclosed arms elevated 63 cm above the ground (Hamilton-Kinder). Mice
were allowed to acclimate to the testing room under dim light for 1 h before
testing. During testing, mice were placed at the junction between the open
and closed arms of the maze and allowed to explore for 5 min. The maze was
cleaned with 70% ethanol (by volume) between testing of each mouse. Total
distance moved and time spent in both the open and closed arms were
calculated for data analysis.
Morris water maze. The Morris water maze test was carried out essentially as
described in ref. 27. A full description is given in SI Materials and Methods.
Novel object recognition. Mice were transferred to the testing room and ac-
climated for at least 1 h before testing. They were tested in a white, round,
plastic chamber (35 cm in diameter) under dim light. On day 1, mice were
habituated to the testing arena for 30 min. On day 2, each mouse was
presented with two identical objects in the same chamber and allowed to
explore freely for 10 min. On day 3, mice were placed back into the same
arena for the test session, during which they were presented with an exact
replica of one of the objects used during training andwith a novel, unfamiliar
object of different shape and texture. Object locations were kept constant
during training and test sessions for any given mouse, but objects were
changed semirandomly among mice. Arenas and objects were cleaned with
70% ethanol (by volume) between each mouse. Mice were videotaped, and
an investigator blind to their genotype and treatment scored the frequency
of interactions and time spent with each object.
Immunohistochemistry. Processing of brain tissues and immunohistochemistry
were performed as described (28, 67). Details are given in SI Materials
and Methods.
Immunoblotting.Western blot analysis was carried out essentially as described
in ref. 27. A full description is given in SI Materials and Methods.
Electrophysiology on Acute Brain Slices. Slices were prepared from 4- to 5-mo-
old NTG and hAPPJ20 mice treated with LEV (75 mg·kg−1·d−1, s.c. osmotic
pumps) or saline for 20–25 d. A full description of brain preparation and
electrophysiological recordings is given in SI Materials and Methods.
ELISA Analysis of Aβ Levels in Brain Tissue. Hippocampi were microdissected
and homogenized in 5 M guanidine buffer. Levels of human Aβ1-x and Aβ1-
42 were analyzed by ELISA as described (68).
In Vivo Aβ Microdialysis. In vivo microdialysis to assess brain ISF Aβ in the
hippocampus of awake, freely moving hAPPJ20 mice was performed as
previously described (69, 70). Mice received saline or LEV (75 mg·kg−1·d−1 s.c.)
for 2 wk by osmotic minipumps (Alzet; Model 2004). On day 13 or 14 of drug
administration, mice underwent in vivo microdialysis to determine absolute
levels of ISF Aβ within the hippocampus. Further details are given in SI
Materials and Methods.
Statistical Analyses. Experimenters who obtained the primary data were
blinded as to the genotype and treatment of mice. Statistical analyses were
performed with GraphPad Prism version 5.0 or with R. Differences between
two means were assessed by unpaired or paired Student’s t test. Differences
among multiple means were assessed, as indicated, by one-way, two-way, or
repeated-measures ANOVA, followed by a Bonferroni test. Two-way ANOVA
was unidirectional because we hypothesized that LEV reverses abnormalities
and dysfunctions in hAPPJ20 mice. Slopes of linear regression curves were
compared by F-test using GraphPad Prism version 5.0. To analyze the results
of the water maze trials we used a repeated measures analysis of covariance
(ANCOVA) to model the distance moved and latency to reach the target,
considering genotype (binary variable) and day (continuous variable) as ex-
planatory variables. This specific analysis was done in R with the nlme pack-
age. Error bars represent SEM. Null hypotheses were rejected at the 0.05 level.
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